Connect with us


3 “Strong Buy” Penny Stocks With Explosive Upside Ahead

3 "Strong Buy" Penny Stocks With Explosive Upside Ahead



What to make of the markets today? We just wrapped up the second quarter, and the S&P 500 registered its best quarter in 70 years, gaining 20%. It was even more impressive as the gains came on the rebound from the worst losses since the Great Depression. We’ve had recessionary pressures thanks to COVID-19, and the sudden burst of positive sentiment, as it became clear that this time, there really is pent-up demand after a collapse.

Looking at the historical pattern of stock market performance following bearish quarters, SunTrust Robinson chief market strategist Keith Lerner sees reason for continued optimism.

“The weight of the evidence in our work still suggests that we are in a bull market… While the fits and starts in the economy and other factors will likely lead to periodic market setbacks, our work suggests this bull market continues to earn the benefit of the doubt, and we retain a positive 12-month outlook,” Lerner noted.

Lerner has backed up by some solid data – and not just the S&P’s past performance patterns. In May, we saw jobs surge as states began to reopen and people went back to work. Retail sales bounced back over 8%, and durable goods orders, a key metric for industrial activity, jumped 15%. With June’s data due out over the course of the coming week, investors are hoping for more good news.

In the meantime, for investors seeking the highest possible upside, we’ve used the TipRanks database to pull up three penny stocks whose potential starts at 105%. These are stocks priced below $5 per share, so even a small gain in absolute terms can translate to a huge percentage gain in share value.

Kaleyra (KLR)

We’ll start with a cloud computing company, Kaleyra. This company offers cloud-based communications platforms, including SMS, voice calling, and data insights, through SaaS model. Kaleyra entered the NYSE last year, after it was purchased by GigCapital in a Silicon Valley acquisition move. The combined entity took on the Kaleyra name.

The coronavirus crisis pushed Kaleyra’s earnings negative in Q1, after the company saw a net profit the quarter before. It’s important to note that Kaleyra is heavily involved in the European market, and its European operations are based in the northern Italian city of Milan, in a region that was hit harder than most by the COVID-19 pandemic.

The company was able to use the crisis to its advantage, offering free texting services to Italian EMS services. It was a smart move that generated goodwill, an important offset to the grim quarterly earnings. Quarterly revenues were a different story. The top line sales hit $33.6 million in Q1, up 21% year-over-year.

With a price tag of $3.95 per share, analysts believe that now is the time to pull the trigger.

Oppenheimer’s 5-star analyst Timothy Horan sees Kaleyra with a clear path forward as the pandemic begins to ebb. Horan writes, “The company's … platform is well-positioned for a number of secular trends that have been accelerated by COVID-19: 1) cloud adoption and digital transformations embed more communications into workflows and applications, 2) growing mobile usage as the number of LTE smartphones more than doubles over the next four years, and 3) increased personalization and automated interaction with customers/ users across every industry.”

"KLR should gain market share in the fast-growing CPaaS sector with its trusted-partner focus. The key is gaining traction with US customers and selling higher value voice/applications. With a below-$200M market cap, we consider the company speculative, appropriate for high-risk-tolerant investors. Positively, Kaleyra has landed world-class customers recently—Facebook, AT&T, Amazon— and we expect major financial services companies soon," the top analyst concluded.

To this end, Horan rates KLR a Buy rating along with a $12 price target. His target suggests an impressive 204% upside potential for the coming year. (To watch Horan’s track record, click here)

The analyst consensus on KLR, a Strong Buy, is unanimous, with all four recent reviews giving the stock a thumbs up. On top of this, KLR's $13.25 average price target implies a hefty upside of 235%. (See KLR stock analysis on TipRanks)

Orion Energy Systems (OESX)

Next on our list is Orion Energy Systems, a “green” manufacturing company that specializes in LED lighting products. The company offers a range of illumination solutions for both indoors and outdoors, and was cited by President Obama in 2009 and 2011 as a leader in the move toward a green economy.

Orion closed out its fiscal year 2020 in its last quarterly report, and showed an impressive 129% annual gain in revenue, to $150.8 million. And, despite the coronavirus-inspired lockdowns, Orion was able to finish the fiscal year with solid liquidity, in the form of $28.8 million in cash on hand.

With the price per share landing at $3.42, some members of the Street see an attractive entry point.

Covering this stock for H.C. Wainwright, analyst Amit Dayal likes what he sees, writing, “We expect revenues to bounce back to $159.7M in FY2022, as the company completes work at 600 remaining locations of its largest customer… We expect FY2021 gross margins to be 22.0%, lower compared to 24.6% in FY2020 as a result of lower revenues, but expect these to grow to over 27.0% during FY2022 and beyond…”

The analyst places a Buy rating on the shares, and his $7 price target implies 105% upside growth in the coming year. (To watch Dayal’s track record, click here)

Wall Street agrees with Dayal, giving OESX a unanimous Strong Buy consensus rating based on 3 Buys. The stock’s $7.58 average price target suggests room for a robust 124% one-year upside potential. (See Orion Energy stock analysis on TipRanks)

S&W Seed Company (SANW)

We round off our list in the agricultural sector, where S&W Seeds is a small-cap player in the world of agribusiness commodities. The company grows and processes a variety of products, including alfalfa, small grains, and wheat, along with sorghum, sunflower, and stevia. In addition to growing the seeds, S&W breeds the varieties it sells.

S&W’s operations and customers are mainly located in the US, but during the first quarter, the company expanded its international reach through the acquisition of Australia’s Pasture Genetics in a deal worth $13.5 million ($20 million in Aussie currency).

Roth Capital analyst Gerry Sweeney sees S&W Seed in a strong competitive position: “While COVID muddies the waters going forward and may create headwinds, we remain optimistic regarding 4Q and F2021 results as core growth remains strong. S&W continues to position itself as middle market seed company with alfalfa, sorghum, sunflower and other varieties. In addition, the Pasture Genetics acquisition bolsters S&W’s distribution platform in Australia and provides cross selling opportunities.”

Sweeney’s $5 price target implies a 120% upside potential for the stock in the coming year, and fully backs his Buy rating. (To watch Sweeney’s track record, click here.)

Overall, SANW is selling for $2.27 per share, and the average price target of $5.33 indicates it has room to grow 134% this year. The stock’s Strong Buy analyst consensus is our third in a row based on a unanimous 3 Buy ratings. (See SANW stock-price forecast on TipRanks)

To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

The post 3 "Strong Buy" Penny Stocks With Explosive Upside Ahead appeared first on TipRanks Financial Blog.

Read More

Continue Reading


IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment

On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European…



On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European Society of Breast Imaging. Their cutting-edge ProSense® System, designed for minimally invasive cryoablation, is marketed and sold worldwide for its cleared indications in the U.S., Europe, and China. More recently they gained approvals in India, and Brazil and have additional distribution through MC Medical to continue expanding in Europe. More importantly, the latest independent study confirms that the technology is a safe & effective outpatient procedure for breast cancer, with 96.8% success rate.

More Background:

Their system has the potential to revolutionize cancer treatment not only for breast cancer, but also for kidney, bone, and lung cancers. To date, the system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

During the event, Dr. Lucía Graña-López, a radiologist specializing in breast and women’s imaging, led an independent study. The study explored cryoablation as a viable alternative to surgery for early-stage breast cancer in patients who preferred a non-surgical route. The results were promising, suggesting that cryoablation could be a successful treatment option, particularly for patients hesitant about traditional surgery.

Subscribe to Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Clinical Study:

The study involved 31 patients with early-stage breast cancer who opted out of surgery, and the outcomes showed that cryoablation was well-tolerated with no major complications. This alternative approach could potentially be a game-changer, especially for breast cancer, which is one of the most prevalent cancers globally. Many patients, particularly older individuals, are seeking less invasive alternatives to surgery, making cryoablation an appealing option.

Dr. Graña-López envisions cryoablation becoming a significant alternative to surgery, particularly for early-stage breast cancer in post-menopausal women. Moreover she believes this technology could reshape how we approach treatment in other indications, particularly for kidney, lung, and thyroid gland cancers.

These results from this independent study are are in line with the ongoing ICE3 study, the largest of its kind in the U.S., set to conclude in early 2024.

We will update you on ICCM when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by marijana1 from Pixabay

The post IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment first appeared on Micro Cap Daily.

The post IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment appeared first on Micro Cap Daily.

Read More

Continue Reading


DAX – PMIs paint a bleak picture for manufacturing but China offers hope

Manufacturing remains in trouble China seeing some growth but unconvincing Bearish confirmation for DE30 index Manufacturing PMIs released throughout the…



  • Manufacturing remains in trouble
  • China seeing some growth but unconvincing
  • Bearish confirmation for DE30 index

Manufacturing PMIs released throughout the day have made for pretty miserable reading and even those in China barely registered any growth after a lengthy period of contraction.

The Chinese data did offer some cause for hope at least, despite ultimately barely sitting in growth territory. The trajectory is positive and boosted by targeted stimulus measures that are seemingly working. External demand remains a problem but a bump in domestic demand is promising.

The sector in Europe is looking particularly grim with demand remaining extremely weak, backlogs falling and layoffs expected to accelerate over the months ahead. That’s unless we can see a rebound in activity which is looking very unlikely at this stage with the global economy struggling for any positive momentum against the backdrop of high interest rates.

The PMIs from the US were a little better, particularly the ISM reading which significantly beat expectations but even here, it remains below 50 and therefore in contraction territory. With interest rates set to remain “higher for longer”, things aren’t likely to dramatically improve for the sector.

A very bearish signal for the DAX

The DE30 turned lower again today after staging a mild recovery in recent sessions and the move could reinforce bearish views on the index.

DE30 Daily

Source – OANDA on Trading View

The reason is that the move lower came after a retest of the 200/233-day simple moving average band, following the breakout last week. The rotation lower now could be viewed as confirmation of the breakout and therefore a bearish signal.

The next potential area of support could be seen around 15,000 where prior support and resistance falls around the bottom of the descending channel.

Read More

Continue Reading


Can An ‘Independent’ Kennedy Destroy “The Whole Left-Right Demon-Driven Pyschodrama”

Can An ‘Independent’ Kennedy Destroy "The Whole Left-Right Demon-Driven Pyschodrama"

Authored by James Howard Kunstler via,





Can An 'Independent' Kennedy Destroy "The Whole Left-Right Demon-Driven Pyschodrama"

Authored by James Howard Kunstler via,


“Intents have been overtaken by events.”

- Jacob Dreizin

You have to wonder what took Bobby Kennedy, Jr. so long to recognize that the Democratic Party was a home that he had long ago been turned out of, like a dog that has peed on the carpet too many times.

At the end of last week, Mr. Kennedy intimated that he might run for president on an independent line.

If he manages to get that line on the state ballots - and you can easily imagine New York and California trying to thwart him - it will change all the current calculations about the 2024 election.

As of right now, the Party of Chaos is living up to its name. They continue to present an obviously false and ridiculous consensus among themselves that “Joe Biden” is running for reelection. In fact, “the Big Guy” is about to get run through a wringer of the most abject public disgrace as his already-well-known crimes of bribery and treason get conscientiously laid out for all to see with cold and implacable decorum. Even the mind-fucked spawn of the Ivy League, toiling away on their CIA-owned newspapers and cable news networks, might find themselves forced to spin their narrative in a new direction.

“Joe Biden” is now a monumental embarrassment and a liability to our country, let alone to the degenerate party that owns him. Sub rosa efforts must be in motion to persuade him to resign before the impeachment inquiry spotlights all those telltale bank records, but they will fail to overcome his demented pride. He’ll ride this thing out to the bitter end, when he can use the last tool at his disposal to officially pardon everyone involved in his family’s racketeering operation. The longer the party pretends to support him, the closer the party itself skates toward self-destruction. Also consider: if allowed to play out, the impeachment inquiry will implicate the DOJ and the FBI in obstruction of justice — exposing many Deep State blob players to danger of prosecution.

Gov Gavin Newsom dangles himself above the fray as the deus ex machina who can touch down in DC and make all the Democrat’s problems go away. Such an attractive fellow! Great teeth and hair! Tall as a sequoia! And such a smooth talker! The woked-up suburban ladies who comprise the party’s main voting bloc grow moist in anticipation of Gov. Newsom landing on-stage like a demigod out of a Mozart opera.

But how do you think he’ll make out in an election when the airwaves are filled with oppo ads showing his toothy and hairy visage inset against scenes of homeless junkies and looting flash mobs? Try blaming that on climate change.

What else does he stand for? Censorship? Forced vaccinations? Child sex mutilations? Open borders? News-flash: these are increasingly unpopular, except among an easily-identified depraved elite.

Indeed, the whole Left-Right demon-driven psychodrama is proving impossible to live in as it throbs and pulsates toward something like civil war. And it has obscured the truly potent idea that the nation might actually be capable of solving its problems by facing up to them and changing how we act. That potent idea might be what voters will see in Bobby Kennedy if he can get their attention. Mr. Kennedy would dismantle the heinous partnerships between private corporations and the US government that loosed the Covid-19 op on the world and asset-strips the middle-class. He favors closing the border and a reevalution of immigration policy. He aims to negotiate an end to the ignoble Ukraine war project. He’s determined to disassemble the security state apparatus that’s destroying the US Constitution and citizens natural rights with it.

Mr. Kennedy says he can bring divided Americans together on these dire matters. It’s conceivable that his message might go over with enough rancor-weary voters to pull off a tour-de-force plurality in a three-way race, where nobody wins enough electoral votes to settle the contest, which then moves to the House, like in the old days of Jefferson and Burr. The rest is election mechanics, some of it very sinister when you consider all the election-rigging booby-traps already in-place such as mass mail-in ballot harvesting, no voter ID requirements, and the still-mysterious hookups of vote-counting machines to the Internet. But, at least, Mr. Kennedy running on an independent line will be a hard whap upside the Democratic Party’s thick skull, maybe even a death-blow to the party. They made a big mistake trying to un-person him. He’s on a hero’s journey at a moment in history when America dearly needs a hero.

*  *  *

Support his blog by visiting Jim’s Patreon Page

Tyler Durden Mon, 10/02/2023 - 16:20

Read More

Continue Reading